Literatur
- 1
Koreth J, Cutler C S, Djulbegovic B. et al .
High-dose therapy with single
autologous transplantation versus chemotherapy for newly diagnosed
multiple myeloma.
Biol Blood Marrow Transplant.
2007;
13
183-196
- 2
Kumar A, Kharfan-Dabaja M A, Glasmacher A, Djulbegovic B.
Tandem
versus single autologous hematopoietic cell transplantation for the
treatment of multiple myeloma.
J Nat Cancer Inst.
2009;
101
100-106
- 3
Ladetto M, Pagliano G, Ferrero S. et al .
Major shrinking of residual tumor cell
burden and achievement of molecular remissions in myeloma patients
undergoing post-transplant consolidation with bortezomib, thalidomide and
dexamethasone.
Blood.
2008;
112
3683
- 4
Rajkumar S V, Jacobus S, Callander N. et al .
A randomized trial of lenalidomide plus
high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone
(Rd) in newly diagnosed multiple myeloma (E4A03): A Trial Coordinated
by the Eastern Cooperative Oncology Group.
Blood.
2007;
110
74
Prof. Dr. Heinz Ludwig
1. Medizinische Abteilung, Zentrum für
Onkologie und Hämatologie, Österreichisches
Forum gegen Krebs, Wilhelminenspital
Montleartstr.
37
1160 Wien
Phone: +43 1/49150-2101
Fax: +43 1/49150-2109
Email: heinz.ludwig@wienkav.at
